(Q35776475)

10 August 2017

1 reference

title

Should insulin-sensitizing drugs be used in the treatment of polycystic ovary syndrome? (English)

1 reference

polycystic ovary syndrome

10 August 2017

1 reference

1 reference

Kai I Cheang

1

1 reference

PubMed ID

15149568

10 August 2017

John E Nestler

series ordinal

2

1 reference

10 August 2017

1 April 2004

1 reference

Reproductive BioMedicine Online

10 August 2017

1 reference

10 August 2017

8

1 reference

10 August 2017

4

1 reference

10 August 2017

440-447

1 reference

Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells

10 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Miscarriage rates following in-vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

The polycystic ovary syndrome: what does insulin resistance have to do with it?

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Identification of placental protein 14 as an immunosuppressive factor in human reproduction

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Lactic acidosis rates in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Impact of obesity on insulin action in volunteers with normal glucose tolerance: demonstration of a threshold for the adverse effect of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Prediction of insulin sensitivity in nonobese women with polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

The measurement of CA 125 and placental protein 14 in uterine flushings in women with recurrent miscarriage; relation to endometrial morphology

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Glucose-to-insulin ratio rather than sex hormone-binding globulin and adiponectin levels is the best predictor of insulin resistance in nonobese women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Paracrine actions of insulin-like growth factors and IGF binding protein-1 in non-pregnant human endometrium and at the decidual-trophoblast interface

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Oral hypoglycaemic agents in 118 diabetic pregnancies.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Effects of metformin on early pregnancy loss in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Reduced serum glycodelin and insulin-like growth factor-binding protein-1 in women with polycystic ovary syndrome during first trimester of pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

The biological variation of testosterone and sex hormone-binding globulin (SHBG) in polycystic ovarian syndrome: implications for SHBG as a surrogate marker of insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Contraindications to the use of metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Secretory endometrium synthesizes placental protein 14

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Identification by Hybridization Histochemistry of Human Endometrial Cells Expressing mRNAs Encoding a Uterine β-Lactoglobulin Homologue and Insulin-Like Growth Factor-Binding Protein-1

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Clinical and laboratory predictors of clomiphene response

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Metformin in polycystic ovary syndrome: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Suppression of serum insulin level by diazoxide does not alter serum testosterone or sex hormone-binding globulin levels in healthy, nonobese women

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Suppression by Human Placental Protein 14 of Natural Killer Cell Activity

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Hypersecretion of luteinising hormone, infertility, and miscarriage

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Recurrent early miscarriage and polycystic ovaries

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Low levels of low molecular weight insulin-like growth factor-binding protein in patients with polycystic ovarian disease

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Habitual abortion is accompanied by low serum levels of placental protein 14 in the luteal phase of the fertile cycle

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Hypersecretion of luteinizing hormone and ovarian steroids in women with recurrent early miscarriage.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960928-5

7 January 2021

10.1016/S1472-6483(10)60928-5

Identifiers

DOI

1 reference

10 August 2017

1 reference

PubMed ID

15149568